03.03.2014 Geratherm Medical AG  DE0005495626

DGAP-News: Geratherm Medical AG: New SRA Technology detects atrial fibrillation at an early stage and prevents strokes


 
DGAP-News: Geratherm Medical AG / Key word(s): Study Geratherm Medical AG: New SRA Technology detects atrial fibrillation at an early stage and prevents strokes 03.03.2014 / 09:28 --------------------------------------------------------------------- Corporate News New SRA Technology detects atrial fibrillation at an early stage and prevents strokes - Results of a multicenter study including 225 participants just published. Study Sponsor: Sanofi-Aventis, Study conduction: Cardiology Platform Hessen - SRA-Technology from apoplex medical convinces in the detection of paroxysmal atrial fibrillation - information about a risk for a threatening stroke prepares the way for early diagnose and preventive measures Apoplex, Geratherm, Pirmasens, 3 March 2014. Cardiological practices in Hessen investigated in a multicenter study including 225 participants over three years the use of a SRA (Stroke Risk Analysis)-based ECG analysis for paroxysmal atrial fibrillation. The SRA-procedure developed by apoplex medical technologies GmbH, Pirmasens, analyses ECG data fully automatic with the goal, to detect atrial fibrillation at an early stage for preventing threatening strokes by applying appropriate therapeutic measures. The results of the study were published on 28 February 2014 by the journal PLOS ONE in San Francisco, USA. The study, sponsored by Sanofi-Aventis, compares conventional ECG examinations with the SRA procedure under conditions of the daily routine in doctor's practices. In 23 from 54 patients without fibrillation episodes, SRA detected a risk for paroxysmal atrial fibrillation (sensitivity 42.6%, specificity 99.0%). Conventional ECG analysis did not indicate atrial fibrillation in these cases. Cardiologically confirmed fibrillation episodes were detected with a sensitivity of 99.2% and a specificity of 99.2%. With these results in the context of a cardiological study, the SRA-technology has impressively proven its excellent performance to detect unknown paroxysmal atrial fibrillation. Background: the high risk for stroke caused by undetected atrial fibrillation causes preventive measures. This implies the detection of the unpredictable paroxysmal atrial fibrillation. Whereas conventional ECG analysis is only successful in the case of present fibrillation episodes, the SRA-technology gives specific hints even in the absence of acute fibrillation. This enables a targeted search for fibrillation episodes and a subsequent appropriate therapy. The free access publication of the study with the title "Improved detection of paroxysmal atrial fibrillation utilizing a software-assisted electrocardiogram approach" is available at: http://apoplexmedical.com/index.php/en/news/studie About apoplex medical technologies apoplex medical technologies GmbH was founded in 2004 in Pirmasens, in the west of the Rhineland-Palatinate, and, within the field of medical technology, specializes in new and innovative technological products for the prevention of strokes throughout the world. The subsidiary of Geratherm Medical AG focuses on easily applicable and efficient methods of patient screening using medical-technical applications to prevent strokes and vascular dementia. The SRA (Stroke Risk Analysis) procedure is the first practicable screening method for paroxysmal atrial fibrillation. It is available in versions for use in medical practices and stroke units. apoplex medical technologies is supported by an extensive academic and clinical network, which professionally supplements its own core competences in the fields of mathematics, physics and medicine. Further information is available at www.apoplexmedical.com. Further information apoplex medical technologies GmbH Albert Hirtz Delaware Avenue 1 - 3 D-66953 Pirmasens fon: +49/(0)6331/698998-0 fax: +49/(0)6331/698998-19 http://www.apoplexmedical.com [email protected] End of Corporate News --------------------------------------------------------------------- 03.03.2014 Dissemination of a Corporate News, transmitted by DGAP - a company of EQS Group AG. The issuer is solely responsible for the content of this announcement. DGAP's Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------- Language: English Company: Geratherm Medical AG Fahrenheitstraße 1 98716 Geschwenda Germany Phone: +49 (0)36205 98-0 Fax: +49 (0)36205 98-1 15 E-mail: [email protected] Internet: www.geratherm.com ISIN: DE0005495626 WKN: 549562 Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin, Düsseldorf, Hamburg, München, Stuttgart End of News DGAP News-Service --------------------------------------------------------------------- 255329 03.03.2014


Die wichtigsten Finanzdaten auf einen Blick
  2015 2016 2017 2018 2019 2020 2021e
Umsatzerlöse1 21,59 21,41 21,03 21,52 19,85 27,47 28,90
EBITDA1,2 3,42 3,71 1,77 2,80 2,35 4,35 5,00
EBITDA-Marge3 15,84 17,33 8,42 13,01 11,84 15,84 17,30
EBIT1,4 2,53 2,54 0,63 1,99 1,05 3,04 3,60
EBIT-Marge5 11,72 11,86 3,00 9,25 5,29 11,07 12,46
Jahresüberschuss1 2,39 2,25 0,22 0,83 0,29 1,90 2,50
Netto-Marge6 11,07 10,51 1,05 3,86 1,46 6,92 8,65
Cashflow1,7 3,77 0,79 2,47 1,35 1,54 3,92 4,55
Ergebnis je Aktie8 0,55 0,45 0,14 0,23 0,11 0,41 0,48
Dividende8 0,50 0,50 0,47 0,40 0,25 0,40 0,42
Quelle: boersengefluester.de und Firmenangaben

  Geschäftsbericht 2020 - Kostenfrei herunterladen.  
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de

Wirtschaftsprüfer: BDO

INVESTOR-INFORMATIONEN
©boersengefluester.de
Geratherm Medical
WKN Kurs in € Einschätzung Börsenwert in Mio. €
549562 9,220 Kaufen 45,64
KGV 2022e KGV 10Y-Ø BGFL-Ratio Shiller-KGV
13,76 25,11 0,55 27,69
KBV KCV KUV EV/EBITDA
2,54 11,66 1,66 10,30
Dividende '20 in € Dividende '21e in € Div.-Rendite '21e
in %
Hauptversammlung
0,40 0,42 4,56 11.06.2021
Q1-Zahlen Q2-Zahlen Q3-Zahlen Bilanz-PK
20.05.2021 25.08.2021 24.11.2021 28.04.2021
Abstand 60Tage-Linie Abstand 200Tage-Linie Performance YtD Performance 52 Wochen
-5,60% -16,11% -15,41% -17,68%
    
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu Geratherm Medical AG  ISIN: DE0005495626 können Sie bei DGAP abrufen

Medtech , 549562 , GME , XETR:GME